View Filing Data

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2010	Dec. 31, 2009
Current assets
Cash and cash equivalents	$ 325,286	$ 207,075
Marketable securities	153,767	134,255
Accounts receivable from the sanofi-aventis Group	79,239	62,703
Accounts receivable - other	3,048	2,865
Prepaid expenses and other current assets	14,379	18,610
Total current assets	575,719	425,508
Restricted cash	3,400	1,600
Marketable securities	37,956	47,080
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	318,498	259,676
Other assets	6,860	7,338
Total assets	942,433	741,202
Current liabilities
Accounts payable and accrued expenses	74,976	49,031
Deferred revenue from sanofi-aventis, current portion	19,335	17,523
Deferred revenue - other, current portion	38,888	27,021
Facility lease obligations, current portion	634	0
Total current liabilities	133,833	93,575
Deferred revenue from sanofi-aventis	99,726	90,933
Deferred revenue - other	197,139	46,951
Facility lease obligation	158,382	109,022
Other long term liabilities	5,289	3,959
Total liabilities	594,369	344,440
Stockholders' equity
Preferred stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding-none	0	0
Common Stock	80	79
Additional paid-in capital	1,379,123	1,336,732
Accumulated deficit	(1,030,966)	(941,095)
Accumulated other comprehensive (loss) income	(175)	1,044
Total stockholders' equity	348,064	396,762
Total liabilities and stockholders' equity	942,433	741,202
Class A [Member]
Stockholders' equity
Common Stock	2	2
Total stockholders' equity	$ 2	$ 2

Per Share Data	9 Months Ended
Per Share Data	Sep. 30, 2010
Notes to Financial Statements [Abstract]
Per Share Data	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"3.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Per Share Data/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s basic and diluted net loss per share amounts have been computed by dividing net lo ss by the weighted average number of shares of Common Stock and Class A Stock outstanding.#160;#160;Net loss per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights.#160;#160;For the three and nine months ended September 30, 2010 and 2009, the Company reported net losses; therefore, no common stock equivalents were included in the computation of diluted net loss per share for these periods, since such inclusion would have been antidilutive.#160;#160;The calculations of basic and diluted net loss per share are as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PA DDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Three Months Ended#160;September 30,/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-B OTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan= "2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2009/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net loss (Numerator)/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TE XT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(33,875/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,015/font ;/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td/trtrtd valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : times new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"W eighted-average shares, in thousands (Denominator)/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"81,638/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" wid th="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"79,866/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style=" TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Basic and diluted net loss per share/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(0.41/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman")/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(0.01/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Nine Months Ended#160;September 30,/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" t;#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2009/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net loss (Numerator)/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: in line; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(89,871/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%" ;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(31,341/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td/trtrtd valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT : 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Weighted-average shares, in thousands (Denominator)/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"81,433/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"79,663/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bo ttom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Basic and diluted net loss per share/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1.10/font/tdtd style="TEXT-ALIGN: le ft" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(0.39/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT - -INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Shares issuable upon the exercise of stock options and vesting of restricted stock awards, which have been excluded from the September 30, 2010 and 2009 diluted per share amounts because their effect would have been antidilutive, include the following:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"div style="D ISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Three months ended September 30,/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; M ARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2009/font/font gt;/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Stock Options:/font/div/tdtd valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Weighted average number, in thousands/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT- ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"21,265/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" ;19,860/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Weighted average exercise price/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman"18.76/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17.65/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%" lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bott om" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Restricted Stock:/font/div/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" w idth="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdt d style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Weighted average number, in thousands/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"511/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"500/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/tr/table/divdiv style="DISPLAY: block; TEXT-IND ENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Nine months ended September 30,/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-S IZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" #160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2009/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZ E: 10pt; FONT-FAMILY: times new roman"Stock Options:/font/div/tdtd valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" amp;#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Weighted average number, in thousands/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"21,317/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-S IZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"20,059/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman"#160;#160;Weighted average exercise price/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"18.67/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left " valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17.59/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td ;td style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Restricted Stock:/font/div/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ti mes new roman"#160;/font/tdtd valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"# 160;#160;Weighted average number, in thousands/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"507/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width ="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"500/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/tr/table/div

Marketable Securities

9 Months Ended

Sep. 30, 2010

Notes to Financial Statements [Abstract]

Marketable Securities

5.	Marketable Securities

Marketable securities at September 30, 2010 and December 31, 2009 consisted of debt securities, as detailed below, and an equity security, the aggregate fair value of which was $4.0 million and $5.5 million at September 30, 2010 and December 31, 2009, respectively, and the aggregate cost basis of which was $4.0 million at both September 30, 2010 and December 31, 2009. The following tables summarize the amortized cost basis of debt securities included in marketable securities, the aggregate fair value of those securities, and gross unrealized gains and losses on those securities at September 30, 2010 and December 31, 2009. The Company classifies its debt securities, other than mortgage-backed securities, based on their contractual maturity dates. Maturities of mortgage-backed securities have been estimated based primarily on repayment characteristics and experience of the senior tranches that the Company holds.

	Amortized	Fair	Unrealized
At September 30, 2010	Cost Basis	Value	Gains	(Losses)	Net
Ma turities within one year
U.S. government obligations	$106,140	$106,238	$101	$(3)	$98
U.S. government guaranteed corporate bonds	44,054	44,237	183		183
U.S. government guaranteed collateralized mortgage obligations	2,481	2,611	130		130
Mortgage-backed securities	689	681		(8)	(8)
	153,364	153,767	414	(11)	403
Maturities between one and five years
U.S. government obligations	9,046	9,072	26		26
U.S. government guaranteed corporate bonds	21,502	21,829	327		327
Municipal bonds	2,206	2,202	4	(8)	(4)
Mortgage-backed securities	842	675

Accounts Payable and Accrued Expenses	9 Months Ended
Accounts Payable and Accrued Expenses	Sep. 30, 2010
Notes to Financial Statements [Abstract]
Accounts Payable and Accrued Expenses	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"6.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Accounts Payable and Accrued Expenses/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Accounts payable and accrued expenses as of September 30, 2010 and December 31, 2009 consist of the following:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"September 30,#160;font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"December 31, font style="DISPLAY: inline"2009/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd v align="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Accounts payable/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"22,576/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="righ t" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"18,638/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Accrued payroll and related costs/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"23,583/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"9,444/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Accrued clinical trial expense/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" gt;#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"14,213/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"11,673/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Accrued property, plant, and equipment expenditures/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"8,495/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap ="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,883/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align=" left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Accrued expenses, other/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,109/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font t;/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,207/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom" align="left"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Payable to Bayer HealthCare/font/div/tdtd style="PADDING-BOTTOM: 2px" valign="bottom" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160; -/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/ tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"1,186/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 4px" valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman"$/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"74,976/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"49,031/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/tr/table/div

Comprehensive Loss	9 Months Ended
Comprehensive Loss	Sep. 30, 2010
Notes to Financial Statements [Abstract]
Comprehensive Loss	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"7.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Comprehensive Income (Loss)/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Comprehensive income (loss) of the Company includes net loss adjusted for the change i n net unrealized gain (loss) on marketable securities, net of any tax effect.#160;#160;For the three and nine months ended September 30, 2010 and 2009, the components of comprehensive income (loss) are:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman"font style="DISPLAY: inline"Three months ended September 30,/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2009/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 1 0pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net loss/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(33,875/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman")/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,015/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Change in net unrealized gain (loss) on marketable securities/font/div/tdtd style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"131/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2,523/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT : 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;Total comprehensive (loss) income/font/div/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(33,744/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : times new roman")/font/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"1,508/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br / ;/divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Nine months ended September 30,/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/ tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2009/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: times new roman"Net loss/font/div/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(89,871/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/tdtd valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLA Y: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(31,341/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Change in net unrealized gain (loss) on marketable securities/font/div/tdtd style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/t dtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(1,219/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"3,651/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;Total comprehensive loss/font/div/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(91,090/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="b ottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(27,690/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td/tr/table/div

Extension of Technology Licensing Agreement with Astellas	9 Months Ended
	Sep. 30, 2010
Notes to Financial Statements [Abstract]
Extension of Technology Licensing Agreement with Astellas	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"8.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Extension of Technology Licensing Agreement with Astellas/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In March 2007, the Company entered into a six-year non-exclusive license agreement with Astellas Pharma Inc. that allows Astellas to utilize the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/fontfont style="DISPLAY: inline; FONT-STYLE: italic"#160;/fonttechnology in its internal research programs to discover human monoclonal antibodies.#160;#160;Under the terms of the agreement, Astellas made a $20.0 million annual, non-refundable payment to the Company in each of 2010, 2009, 2008, and 2007.#160;#160;In July 2010, the license agreement with Astellas was amended and extended through June 2023.#160;#160;Under the terms of the amended agreement, Astellas made a $165.0 million up-front payment to the Company in August 2010, which font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"was deferred upon receipt and will be recognized as revenue ratably over the seven-year period beginning in mid-2011./font#160;#160;In addition, Astellas will make a $130.0 million second payment to the Company in June 2018 unless the license agreement has been terminated prior to that date.#160;#160;Astellas has the right to terminate the agreement at any time by providing 90 days#8217; advance written notice.#160;#160;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"Under certain limited circumstances, such as a material breach of the agreement by the Company, Astellas may terminate the agreement and receive a refund of a portion of its up-front payment or, if such termination occurs after June 2018, a portion of its second payment, to the Company under the July 2010 amendment to the agreement./font#160;#160;The Company is entitled to receive a mid-single-digit royalty on any future sales of antibody products discovered by Astellas using the Company#8217;s font style="DISPLAY: i nline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font technology.#160;#160;In connection with the Astellas license agreement, the Company recognized $15.0 million of technology revenue for both the nine months ended September 30, 2010 and 2009.#160;#160;In addition, deferred revenue at September 30, 2010 and December 31, 2009 was $178.7 million and $8.7 million, respectively./font/div

Entity Information - USD ($)	9 Months Ended
Entity Information - USD ($)	Sep. 30, 2010	Oct. 15, 2010	Jun. 30, 2009
Entity Registrant Name	REGENERON PHARMACEUTICALS INC
Entity Central Index Key	0000872589
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 1,355,426,000
Entity Common Stock, Shares Outstanding		80,111,128
Document Fiscal Year Focus	2010
Document Fiscal Period Focus	Q3

PARENTHETICAL DISCLOSURE TO THE CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2010	Dec. 31, 2009
Stockholders' equity
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	30,000,000	30,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, authorized	160,000,000	160,000,000
Common Stock, issued	80,042,523	78,860,862
Common Stock, outstanding	80,042,523	78,860,862
Class A [Member]
Stockholders' equity
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, authorized	40,000,000	40,000,000
Common Stock, issued	2,181,831	2,244,698
Common Stock, outstanding	2,181,831	2,244,698

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
CONDENSED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2010	Sep. 30, 2009	Sep. 30, 2010	Sep. 30, 2009
Revenues
Sanofi-aventis collaboration revenue	$ 75,583,000	$ 68,536,000	$ 229,195,000	$ 178,928,000
Other collaboration revenue	13,761,000	32,153,000	40,483,000	54,947,000
Technology licensing	10,037,000	10,000,000	30,112,000	30,000,000
Net product sales	4,936,000	4,973,000	19,985,000	13,364,000
Contract research and other	1,662,000	1,793,000	5,624,000	5,229,000
Total Revenues	105,979,000	117,455,000	325,399,000	282,468,000
Expenses
Research and development	122,043,000	105,434,000	364,040,000	279,972,000
Selling, general, and administrative	15,658,000	12,840,000	44,560,000	35,892,000
Cost of goods sold	372,000	472,000	1,494,000	1,299,000
Total Expenses	138,073,000	118,746,000	410,094,000	317,163,000
Loss from operations	(32,094,000)	(1,291,000)	(84,695,000)	(34,695,000)
Other income (expense)
Investment income	453,000	857,000	1,484,000	3,935,000
Interest expense	(2,234,000)	(581,000)	(6,660,000)	(581,000)
Total Other Income (Expense)	(1,781,000)	276,000	(5,176,000)	3,354,000
Net loss	(33,875,000)	(1,015,000)	(89,871,000)	(31,341,000)
Net loss per share, basic and diluted	$ (0.41)	$ (0.01)	$ (1.10)	$ (0.39)
Weighted average shares outstanding, basic and diluted	81,638	79,866	81,433	79,663

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2010	Sep. 30, 2009	Sep. 30, 2010	Sep. 30, 2009
Statement [Line Items]
Beginning Balance			$ 396,762	$ 421,514
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered			13,194	4,626
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution			2,867	1,391
Stock-based compensation expense			26,331	22,602
Net loss	$ (33,875)	$ (1,015)	(89,871)	(31,341)
Change in net unrealized gain (loss) on marketable securities			(1,219)	3,651
Ending Balance	$ 348,064	$ 422,443	$ 348,064	$ 422,443
Class A [Member]
Statement [Line Items]
Beginning Balance (in shares)			2,245	2,249
Beginning Balance			$ 2	$ 2
Conversion of Class A Stock to Common Stock (in shares)			(63)	(2)
Ending Balance (in shares)	2,182	2,247	2,182	2,247
Ending Balance	$ 2	$ 2	$ 2	$ 2
Common Stock [Member]
Statement [Line Items]
Beginning Balance (in shares)			78,861	77,642
Beginning Balance			$ 79	$ 78
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered (in shares)			993	518
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered			$ 1
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)			111	81
Issuance of Restricted Common Stock under Long-Term Incentive Plan (in shares)			15
Conversion of Class A Stock to Common Stock (in shares)			63	2
Ending Balance (in shares)	80,043	78,243	80,043	78,243
Ending Balance	$ 80	$ 78	$ 80	$ 78
Additional Paid-in Capital [Member]
Statement [Line Items]
Beginning Balance			1,336,732	1,294,813
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered			13,193	4,626
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution			2,867	1,391
Stock-based compensation expense			26,331	22,602
Ending Balance	1,379,123	1,323,432	1,379,123	1,323,432
Accumulated Deficit [Member]
Statement [Line Items]
Beginning Balance			(941,095)	(873,265)
Net loss			(89,871)	(31,341)
Ending Balance	(1,030,966)	(904,606)	(1,030,966)	(904,606)
Accumulated Other Comprehensive Income (Loss) [Member]
Statement [Line Items]
Beginning Balance			1,044	(114)
Change in net unrealized gain (loss) on marketable securities			(1,219)	3,651
Ending Balance	(175)	3,537	(175)	3,537
Comprehensive Loss [Member]
Statement [Line Items]
Net loss			(89,871)	(31,341)
Change in net unrealized gain (loss) on marketable securities			(1,219)	3,651
Ending Balance	$ (91,090)	$ (27,690)	$ (91,090)	$ (27,690)

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Sep. 30, 2010	Sep. 30, 2009
Cash flows from operating activities
Net loss	$ (89,871)	$ (31,341)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization	13,601	9,312
Non-cash compensation expense	26,331	22,602
Net realized loss (gain) on marketable securities	242	(56)
Changes in assets and liabilities
Increase in accounts receivable	(16,719)	(32,554)
Decrease (increase) in prepaid expenses and other assets	3,446	(370)
Increase (decrease) in deferred revenue	172,660	(11,379)
Increase in accounts payable, accrued expenses, and other liabilities	28,353	17,960
Total adjustments	227,914	5,515
Net cash provided by (used in) operating activities	138,043	(25,826)
Cash flows from investing activities
Purchases of marketable securities	(241,665)	(190,666)
Sales or maturities of marketable securities	230,513	284,934
Capital expenditures	(67,427)	(75,002)
(Increase) decrease in restricted cash	(1,800)	50
Net cash (used in) provided by investing activities	(80,379)	19,316
Cash flows from financing activities
Proceeds in connection with facility lease obligations	47,544	5,182
Payments in connection with facility lease obligations	(757)	(773)
Net proceeds from the issuance of Common Stock	13,760	4,626
Net cash provided by financing activities	60,547	9,035
Net increase in cash and cash equivalents	118,211	2,525
Cash and cash equivalents at beginning of period	207,075	247,796
Cash and cash equivalents at end of period	$ 325,286	$ 250,321

ARCALYST (rilonacept) Product Revenue	9 Months Ended
ARCALYST (rilonacept) Product Revenue	Sep. 30, 2010
Notes to Financial Statements [Abstract]
ARCALYST (rilonacept) Product Revenue	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font (rilonacept) Product Revenue/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY : Times New Roman"In February 2008, the Company received marketing approval from the U.S. Food and Drug Administration (#8220;FDA#8221;) for ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font Injection for Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes (#8220;CAPS#8221;).#160;#160;The Company had limited historical return experience for ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font beginning with initial sales in 2008 through the end of 2009; therefore, ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales were deferred until the right of return no longer existed and rebates could be reasonably estimated.#160;#160;Effective in the first quarter of 2010, the Company determined that it had accumulated sufficient historical data to reasonably e stimate both product returns and rebates of ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font.#160;#160;As a result, $4.8 million of previously deferred ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales were recognized as revenue in the first quarter of 2010./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales totaled $4.9 million and $5.0 million for the three months ended September 30, 2010 and 2009, respectively, and $20.0 million and $13.4 million for the nine months ended September 30, 2010 and 2009, respectively.#160;#160;ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174; /fontnet product sales during the first nine months of 2010 included $15.2 million of net product sales made during this period and $4.8 million of previously deferred net product sales, as described above.#160;#160;There was no deferred ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales revenue at September 30, 2010.#160;#160;At September 30, 2009, deferred ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales revenue was $5.0 million.#160;#160;The effect of this change in estimate related to ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales revenue was to lower the Company#8217;s net loss per share by $0.06 for the nine months ended September 30, 2010./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Cost of goods sold related to ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font sales, which consisted primarily of royalties, totaled $0.4 million and $0.5 million for the three months ended September 30, 2010 and 2009, respectively, and $1.5 million and $1.3 million for the nine months ended September 30, 2010 and 2009, respectively.#160;#160;To date, ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font shipments to the Company#8217;s customers have consisted of supplies of inventory manufactured and expensed prior to FDA approval of ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font for the treatment of CAPS; therefore, the costs of these supplies were not included in costs of goods sold.#160;#160;At both September 30, 2010 and December 31, 2009, the Company had $0.4 million of inventoried work-in-process costs related to ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font, which is included in prepaid expenses and other current assets./font/div

Statement of Cash Flows	9 Months Ended
Statement of Cash Flows	Sep. 30, 2010
Notes to Financial Statements [Abstract]
Statement of Cash Flows	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Statement of Cash Flows/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Supplemental disclosure of noncash investing and financing activities:/font ;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in accounts payable and accrued expenses at September 30, 2010 and December 31, 2009 were $12.0 million and $9.8 million, respectively, of accrued capital expenditures.#160;#160;Included in accounts payable and accrued expenses at September 30, 2009 and December 31, 2008 were $10.5 million and $7.0 million, respectively, of accrued capital expenditures./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in accounts payable and accrued expenses at December 31, 2009 and 2008 w ere $2.6 million and $1.5 million, respectively, of accrued Company 401(k) Savings Plan contribution expense.#160;#160;In the first quarter of 2010 and 2009, the Company contributed 111,419 and 81,086 shares, respectively, of Common Stock to the 401(k) Savings Plan in satisfaction of these obligations./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Pursuant to the application of authoritative guidance issued by the Financial Accounting Standards Board (#8220;FASB#8221;) to the Company#8217;s lease of office and laboratory facilities in Tarrytown, New York, the Company recognized a facility lease obligation of $4.0 million for the nine months ended September 30, 2009, in connection with capitalizing, on the Company#8217;s books, the landlord amp;#8217;s costs of constructing new facilities that the Company has leased./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in facility lease obligations and property, plant, and equipment at September 30, 2010 was $2.6 million of capitalized and deferred interest for the nine months ended September 30, 2010, as the related facilities being leased by the Company are currently under construction and lease payments on these facilities do not commence until January 2011./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in other assets at September 30, 2010 and December 31, 2009 was $0.1 million and $0.7 million, respectively, due to the Company in connection with employee exercises of stock options./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in marketable securities at September 30, 2010 and December 31, 2009 were $1.3 million and $0.6 million, respectively, of accrued interest income.#160;#160;Included in marketable securities at September 30, 2009 and December 31, 2008 were $1.0 million and $1.7 million, respectively, of accrued interest income./font/div